XML 28 R7.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Millions, $ in Millions
Total
Total Edwards Lifesciences Corporation Stockholders' Equity
Common Stock
Treasury Stock
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Noncontrolling Interest
Common stock, beginning balance (in shares) at Dec. 31, 2021     642.0          
Beginning balance at Dec. 31, 2021 $ 5,835.9   $ 642.0 $ (2,416.9) $ 1,700.4 $ 6,068.1 $ (157.7)  
Treasury stock, beginning balance (in shares) at Dec. 31, 2021       17.9        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 373.6         373.6    
Other comprehensive loss, net of tax (28.9)           (28.9)  
Common stock issued under stock plans (in shares)     0.9          
Common stock issued under stock plans 37.5   $ 0.9   36.6      
Stock-based compensation expense 32.4       32.4      
Purchases of treasury stock (in shares)       3.6        
Purchases of treasury stock (405.6)     $ (405.6)        
Common stock, ending balance (in shares) at Mar. 31, 2022     642.9          
Ending balance at Mar. 31, 2022 5,844.9   $ 642.9 $ (2,822.5) 1,769.4 6,441.7 (186.6)  
Treasury stock, ending balance (in shares) at Mar. 31, 2022       21.5        
Common stock, beginning balance (in shares) at Dec. 31, 2021     642.0          
Beginning balance at Dec. 31, 2021 5,835.9   $ 642.0 $ (2,416.9) 1,700.4 6,068.1 (157.7)  
Treasury stock, beginning balance (in shares) at Dec. 31, 2021       17.9        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 780.0              
Common stock, ending balance (in shares) at Jun. 30, 2022     645.0          
Ending balance at Jun. 30, 2022 5,943.6   $ 645.0 $ (3,177.6) 1,852.5 6,848.1 (224.4)  
Treasury stock, ending balance (in shares) at Jun. 30, 2022       25.2        
Common stock, beginning balance (in shares) at Mar. 31, 2022     642.9          
Beginning balance at Mar. 31, 2022 5,844.9   $ 642.9 $ (2,822.5) 1,769.4 6,441.7 (186.6)  
Treasury stock, beginning balance (in shares) at Mar. 31, 2022       21.5        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 406.4         406.4    
Other comprehensive loss, net of tax (37.8)           (37.8)  
Common stock issued under stock plans (in shares)     2.1          
Common stock issued under stock plans 49.0   $ 2.1   46.9      
Stock-based compensation expense 36.2       36.2      
Purchases of treasury stock (in shares)       3.7        
Purchases of treasury stock (355.1)     $ (355.1)        
Common stock, ending balance (in shares) at Jun. 30, 2022     645.0          
Ending balance at Jun. 30, 2022 $ 5,943.6   $ 645.0 $ (3,177.6) 1,852.5 6,848.1 (224.4)  
Treasury stock, ending balance (in shares) at Jun. 30, 2022       25.2        
Common stock, beginning balance (in shares) at Dec. 31, 2022 608.3   646.3          
Beginning balance at Dec. 31, 2022 $ 5,806.7 $ 5,806.7 $ 646.3 $ (4,144.0) 1,969.3 7,590.0 (254.9) $ 0.0
Treasury stock, beginning balance (in shares) at Dec. 31, 2022 38.0     38.0        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income $ 340.5 340.5       340.5    
Other comprehensive loss, net of tax (0.5) (0.5)         (0.5)  
Common stock issued under stock plans (in shares)     0.8          
Common stock issued under stock plans 41.9 41.9 $ 0.8   41.1      
Stock-based compensation expense 38.9 38.9     38.9      
Purchases of treasury stock (in shares)       3.1        
Purchases of treasury stock (249.5) (249.5)   $ (249.5)        
Changes to noncontrolling interest 84.0             84.0
Common stock, ending balance (in shares) at Mar. 31, 2023     647.1          
Ending balance at Mar. 31, 2023 $ 6,062.0 5,978.0 $ 647.1 $ (4,393.5) 2,049.3 7,930.5 (255.4) 84.0
Treasury stock, ending balance (in shares) at Mar. 31, 2023       41.1        
Common stock, beginning balance (in shares) at Dec. 31, 2022 608.3   646.3          
Beginning balance at Dec. 31, 2022 $ 5,806.7 5,806.7 $ 646.3 $ (4,144.0) 1,969.3 7,590.0 (254.9) 0.0
Treasury stock, beginning balance (in shares) at Dec. 31, 2022 38.0     38.0        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income $ 646.0              
Common stock, ending balance (in shares) at Jun. 30, 2023 607.9   649.1          
Ending balance at Jun. 30, 2023 $ 6,446.5 6,375.7 $ 649.1 $ (4,401.0) 2,145.5 8,237.6 (255.5) 70.8
Treasury stock, ending balance (in shares) at Jun. 30, 2023 41.2     41.2        
Common stock, beginning balance (in shares) at Mar. 31, 2023     647.1          
Beginning balance at Mar. 31, 2023 $ 6,062.0 5,978.0 $ 647.1 $ (4,393.5) 2,049.3 7,930.5 (255.4) 84.0
Treasury stock, beginning balance (in shares) at Mar. 31, 2023       41.1        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 305.5 307.1       307.1   (1.6)
Other comprehensive loss, net of tax (0.1) (0.1)         (0.1)  
Common stock issued under stock plans (in shares)     2.0          
Common stock issued under stock plans 60.8 60.8 $ 2.0   58.8      
Stock-based compensation expense 37.4 37.4     37.4      
Purchases of treasury stock (in shares)       0.1        
Purchases of treasury stock (7.5) (7.5)   $ (7.5)        
Changes to noncontrolling interest $ (11.6)             (11.6)
Common stock, ending balance (in shares) at Jun. 30, 2023 607.9   649.1          
Ending balance at Jun. 30, 2023 $ 6,446.5 $ 6,375.7 $ 649.1 $ (4,401.0) $ 2,145.5 $ 8,237.6 $ (255.5) $ 70.8
Treasury stock, ending balance (in shares) at Jun. 30, 2023 41.2     41.2